Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

YESAFILI

AFLIBERCEPT-JBVF

Standard Dose
2MG(0.05ML,40MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview YESAFILI is listed in Drugs@FDA under application 761274 (BLA).

Review priority: N/A Marketing status: Prescription Active ingredient AFLIBERCEPT-JBVF Form and strength INJECTABLE;INJECTION - 2MG(0.05ML,40MG/ML) Sponsor BIOCON BIOLOGICS INC Submission history Latest submission status date: 2026-01-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview YESAFILI is listed in Drugs@FDA under application 761274 (BLA). Review priority: N/A Marketing status: Prescription Active ingredient AFLIBERCEPT-JBVF Form and strength INJECTABLE;INJECTION - 2MG(0.05ML,40MG/ML) Sponsor BIOCON BIOLOGICS INC Submission history Latest submission status date: 2026-01-13 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.